Harpreet S. Dhaliwal net worth and biography

Harpreet Dhaliwal Biography and Net Worth

Insider of Vaxcyte

Mr. Dhaliwal has 25 years of experience in engineering, operations strategy, manufacturing and supply chain, with significant expertise in the healthcare industry. During his career, he has led commercial manufacturing and supply chain for multiple products. Most recently, Mr. Dhaliwal served as Senior Vice President of Supply Chain, Manufacturing and Procurement at Dermira and transitioned to Eli Lilly following the company’s acquisition. In this role, he supported Dermira’s first product launch and successfully transitioned the cGMP manufacturing network from clinical to commercial. Previously, Mr. Dhaliwal was the Head of Manufacturing and Supply Chain at Medivation, an oncology-focused company. Following Pfizer’s acquisition of Medivation, Mr. Dhaliwal led the operations integration. Previously, Mr. Dhaliwal had a long career at Biogen where he ultimately served as Biogen’s Chief Procurement Officer, responsible for managing $3 billion of enterprise-wide spend. While at Biogen, he was also instrumental in transforming the manufacturing network, initiating the biosimilar business and other strategic initiatives. Mr. Dhaliwal has an MBA in Science and Technology from Queen's University and a Bachelor of Chemical Engineering from the University of British Columbia.

What is Harpreet S. Dhaliwal's net worth?: The estimated net worth of Harpreet S. Dhaliwal is at least $1.14 million as of December 31st, 2025. Dhaliwal owns 23,928 shares of Vaxcyte stock worth more than $1,135,144 as of January 15th. This net worth approximation does not reflect any other assets that Dhaliwal may own. Learn More about Harpreet S. Dhaliwal's net worth.
How do I contact Harpreet S. Dhaliwal?: The corporate mailing address for Dhaliwal and other Vaxcyte executives is 353 HATCH DRIVE, FOSTER CITY CA, 94404. Vaxcyte can also be reached via phone at 650-837-0111 and via email at [email protected]. Learn More on Harpreet S. Dhaliwal's contact information.
Has Harpreet S. Dhaliwal been buying or selling shares of Vaxcyte?: Harpreet S. Dhaliwal has not been actively trading shares of Vaxcyte in the last ninety days. Most recently, Harpreet S. Dhaliwal sold 9,743 shares of the business's stock in a transaction on Wednesday, December 31st. The shares were sold at an average price of $46.69, for a transaction totalling $454,900.67. Following the completion of the sale, the insider now directly owns 23,928 shares of the company's stock, valued at $1,117,198.32. Learn More on Harpreet S. Dhaliwal's trading history.
Who are Vaxcyte's active insiders?: Vaxcyte's insider roster includes Elvia Cowan (SVP), Harpreet Dhaliwal (Insider), Mikhail Eydelman (SVP), Jeff Fairman (VP), Halley Gilbert (Director), Andrew Guggenhime (CFO), Teri Loxam (Director), Heath Lukatch (Director), Grant Pickering (CEO), Paul Sauer (SVP), James Wassil (COO), Jim Wassil (COO), and Jane Wright-Mitchell (General Counsel). Learn More on Vaxcyte's active insiders.
Are insiders buying or selling shares of Vaxcyte?: In the last year, insiders at the sold shares 7 times. They sold a total of 59,616 shares worth more than $4,182,612.33. The most recent insider tranaction occured on December, 31st when insider Harpreet S Dhaliwal sold 9,743 shares worth more than $454,900.67. Insiders at Vaxcyte own 3.1% of the company. Learn More about insider trades at Vaxcyte.
Information on this page was last updated on 12/31/2025.

Harpreet S. Dhaliwal Insider Trading History at Vaxcyte

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/31/2025	Sell	9,743	$46.69	$454,900.67	23,928

Harpreet S. Dhaliwal Buying and Selling Activity at Vaxcyte

Vaxcyte Company Overview

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Today's Range

Now: $48.51

$46.88

$48.91

50 Day Range

MA: $46.31

$41.65

$50.24

2 Week Range

Now: $48.51

$27.66

$93.77

Volume

184,775 shs

Average Volume

940,316 shs

Market Capitalization

$6.35 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.34